 | | Vol. 6.31 – 21 August, 2020 |
| |
|
|
| Scientists demonstrated that the tumorigenic subpopulation of mouse LGR5+ cells existed in a slow-cycling state and identified a unique 22-gene signature that characterized these slow-cycling cancer stem cell.
[Cancer Research] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| The RAS-ERK1/2 axis controlled expression of the cytokine ANGPT2 and the cytokine receptor CXCR4 in colorectal cancer cells, which facilitated development of liver but not lung metastases, suggesting that ANGPT2 and CXCR4 were important for metastatic outgrowth in the liver.
[Cancer Research] |
|
|
|
| Investigators report that high dietary linoleic acid promoted colorectal carcinogenesis in mice treated with azoxymethane or with an intestinally targeted Apc mutation by upregulating Wnt receptor LRP5 protein expression and β-catenin activation.
[Cell Reports] |
|
|
|
| Researchers demonstrated that sclerostin domain containing-1 promoted invasion and liver metastasis in colorectal cancer, by overcoming BMP4-specific antimetastatic signals and inducing ALCAM-mediated Src and PI3K/AKT activation.
[Oncogene] |
|
|
|
| Proteomics and kinase analysis revealed that a physiologically, but nonconventionally, spliced Cdc42 variant 2 (V2) exhibited stronger MAPK-activating capability. Mice engineered to overexpress Cdc42-V2 in intestinal epithelium showed elevated MAPK signaling, enhanced regeneration, and reduced mucosal damage in response to irradiation. Overproducing Cdc42-V2 specifically in mouse intestinal stem cells enhanced intestinal regeneration following injury.
[JCI Insight] |
|
|
|
| Investigators found a reciprocal relationship between Farnesoid X receptor (FXR) and β-catenin. Loss of β-catenin increased the transcriptional activation of SHP by FXR.
[Cell Death & Disease] |
|
|
|
| Scientists elucidated the mechanism by which leukotriene C4 (LTC4) – induced 15-hydroxyprostaglandin dehydrogenase (15-PGDH) promoted differentiation in colon cancer cells through cysteinyl leukotriene receptor 2 activation with the involvement of Hedgehog–GLI signalling. They observed that GLI1 was involved in the regulation of the redifferentiation and reduction in stemness induced by LTC4 via 15-PGDH in colon cancer cells.
[Oncogenesis] |
|
|
|
| The authors identified potential GLI1 binding sites in the promoter region of six ABC transporters. Next, they investigated the binding of GLI1 using chromatin immunoprecipitation experiments and demonstrated that GLI1 transcriptionally regulated the identified ABC transporters. This research showed that chemoresistant cells express high levels of GLI1 and of the ABC transporters and that GLI1 inhibition disrupted the transporters up-regulation.
[Scientific Reports] |
|
|
|
| TMPRSS13 silencing in colorectal cancer (CRC) cell lines increased apoptosis and impaired invasive potential. Transgenic overexpression of TMPRSS13 in CRC cell lines increased tolerance to apoptosis-inducing agents, including paclitaxel and HA14-1. Conversely, TMPRSS13 silencing rendered CRC cells more sensitive to these agents.
[Scientific Reports] |
|
|
|
| Investigators showed that BAH dose-dependently enhanced collagen gel contraction and activated the hypoxia-inducing factor pathway in NIH-3T3 fibroblasts; BAH treatment also prevented the loss of trans-epithelial electrical resistance induced by proinflammatory cytokines in Caco-2 cells.
[Acta Pharmacologica Sinica] |
|
|
|
|
| The intestine shows multiple alterations during aging. While the main function of nutrient absorption is relatively well maintained, capacity of the intestine to respond to abrupt changes or damage declines with age. The authors highlight recent evidence on age-associated changes in the ISC function, and focuses on stem cell extrinsic mechanisms.
[Mechanisms of Ageing and Development] |
|
|
|
|
| Immunic, Inc.announced dosing of the first healthy volunteer in the company’s phase I clinical program of IMU-856, an orally available, small molecule modulator that targets a yet undisclosed protein which serves as a transcriptional regulator of intestinal barrier function.
[Immunic Therapeutics Inc.] |
|
|
|
| Qu Biologics Inc. has announced approval from the Israeli Ministry of Health to proceed with their clinical trial of QBECO Site Specific Immunomodulator (SSI) in patients with colorectal cancer. The study, “Assessment of QBECO SSI on Immunological Parameters in the Tumor Microenvironment and Systemically in Patients with Colorectal Cancer” will enrol patients at the Sheba Medical Center with Principal Investigator, Dr. Gal Markel.
[Qu Biologics Inc.] |
|
|
|
|
| Sep 7 – 11, 2022
Woods Hole, Massachusetts, United States |
|
|
|
|
|
| | City of Hope – Monrovia, California, United States |
|
|
|
| | USC Lawrence J. Ellison Institute for Transformative Medicine – West Los Angeles, California, United States |
|
|
|
| | University of Kentucky – Lexington, Kentucky, United States |
|
|
|
| | Emory University – Atlanta, Georgia, United States |
|
|
|
| | Baylor College of Medicine – Houston, Texas, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
